Initial clinical studies of vindesine

M. Valdivieso, Stephen P Richman, A. M. Burgess, G. P. Bodey, E. J. Freireich

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68 humans with advanced, refractory malignancies. Patients received single total doses ranging from 2 to 12.5 mg, repeated every 1-2 weeks. Dose-limiting myelosuppressive, gastrointestinal, and neurologic toxic effects were observed at higher doses. They consisted predominantly of neutropenia, constipation leading, on occasion, to paralytic ileus, and peripheral neuropathy. Total doses of 7.5-10 mg (equivalent to 4-5 mg/m 2), repeated every 2 weeks, were well-tolerated. These were two partial remissions in patients with acute leukemia and prior vincristine therapy, two minor responses in patients with renal cell carcinoma, one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the lung. Vindesine is well-tolerated by man, although it shares some of the toxic manifestations of vinblastine and vincristine. Its efficacy in some patients who were no longer responsive to vincristine therapy suggests a lack of clinical cross-resistance between these compounds.

Original languageEnglish
Pages (from-to)873-875
Number of pages3
JournalCancer Treatment Reports
Volume65
Issue number9-10
StatePublished - Nov 6 1981
Externally publishedYes

Fingerprint

Vindesine
Vincristine
Squamous Cell Carcinoma
Poisons
Esophagus
Vinca Alkaloids
Intestinal Pseudo-Obstruction
Vinblastine
Peripheral Nervous System Diseases
Constipation
Clinical Studies
Neutropenia
Renal Cell Carcinoma
Nervous System
Leukemia
Lung
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Valdivieso, M., Richman, S. P., Burgess, A. M., Bodey, G. P., & Freireich, E. J. (1981). Initial clinical studies of vindesine. Cancer Treatment Reports, 65(9-10), 873-875.

Initial clinical studies of vindesine. / Valdivieso, M.; Richman, Stephen P; Burgess, A. M.; Bodey, G. P.; Freireich, E. J.

In: Cancer Treatment Reports, Vol. 65, No. 9-10, 06.11.1981, p. 873-875.

Research output: Contribution to journalArticle

Valdivieso, M, Richman, SP, Burgess, AM, Bodey, GP & Freireich, EJ 1981, 'Initial clinical studies of vindesine', Cancer Treatment Reports, vol. 65, no. 9-10, pp. 873-875.
Valdivieso M, Richman SP, Burgess AM, Bodey GP, Freireich EJ. Initial clinical studies of vindesine. Cancer Treatment Reports. 1981 Nov 6;65(9-10):873-875.
Valdivieso, M. ; Richman, Stephen P ; Burgess, A. M. ; Bodey, G. P. ; Freireich, E. J. / Initial clinical studies of vindesine. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 9-10. pp. 873-875.
@article{b94f3795e3f24e0a8eaff9285fd13270,
title = "Initial clinical studies of vindesine",
abstract = "Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68 humans with advanced, refractory malignancies. Patients received single total doses ranging from 2 to 12.5 mg, repeated every 1-2 weeks. Dose-limiting myelosuppressive, gastrointestinal, and neurologic toxic effects were observed at higher doses. They consisted predominantly of neutropenia, constipation leading, on occasion, to paralytic ileus, and peripheral neuropathy. Total doses of 7.5-10 mg (equivalent to 4-5 mg/m 2), repeated every 2 weeks, were well-tolerated. These were two partial remissions in patients with acute leukemia and prior vincristine therapy, two minor responses in patients with renal cell carcinoma, one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the lung. Vindesine is well-tolerated by man, although it shares some of the toxic manifestations of vinblastine and vincristine. Its efficacy in some patients who were no longer responsive to vincristine therapy suggests a lack of clinical cross-resistance between these compounds.",
author = "M. Valdivieso and Richman, {Stephen P} and Burgess, {A. M.} and Bodey, {G. P.} and Freireich, {E. J.}",
year = "1981",
month = "11",
day = "6",
language = "English",
volume = "65",
pages = "873--875",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9-10",

}

TY - JOUR

T1 - Initial clinical studies of vindesine

AU - Valdivieso, M.

AU - Richman, Stephen P

AU - Burgess, A. M.

AU - Bodey, G. P.

AU - Freireich, E. J.

PY - 1981/11/6

Y1 - 1981/11/6

N2 - Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68 humans with advanced, refractory malignancies. Patients received single total doses ranging from 2 to 12.5 mg, repeated every 1-2 weeks. Dose-limiting myelosuppressive, gastrointestinal, and neurologic toxic effects were observed at higher doses. They consisted predominantly of neutropenia, constipation leading, on occasion, to paralytic ileus, and peripheral neuropathy. Total doses of 7.5-10 mg (equivalent to 4-5 mg/m 2), repeated every 2 weeks, were well-tolerated. These were two partial remissions in patients with acute leukemia and prior vincristine therapy, two minor responses in patients with renal cell carcinoma, one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the lung. Vindesine is well-tolerated by man, although it shares some of the toxic manifestations of vinblastine and vincristine. Its efficacy in some patients who were no longer responsive to vincristine therapy suggests a lack of clinical cross-resistance between these compounds.

AB - Vindesine, a newer vinca alkaloid derivative, underwent a phase I clinical evaluation in 68 humans with advanced, refractory malignancies. Patients received single total doses ranging from 2 to 12.5 mg, repeated every 1-2 weeks. Dose-limiting myelosuppressive, gastrointestinal, and neurologic toxic effects were observed at higher doses. They consisted predominantly of neutropenia, constipation leading, on occasion, to paralytic ileus, and peripheral neuropathy. Total doses of 7.5-10 mg (equivalent to 4-5 mg/m 2), repeated every 2 weeks, were well-tolerated. These were two partial remissions in patients with acute leukemia and prior vincristine therapy, two minor responses in patients with renal cell carcinoma, one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the esophagus, and one minor response in a patient with squamous cell carcinoma of the lung. Vindesine is well-tolerated by man, although it shares some of the toxic manifestations of vinblastine and vincristine. Its efficacy in some patients who were no longer responsive to vincristine therapy suggests a lack of clinical cross-resistance between these compounds.

UR - http://www.scopus.com/inward/record.url?scp=0019442159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019442159&partnerID=8YFLogxK

M3 - Article

C2 - 6268296

AN - SCOPUS:0019442159

VL - 65

SP - 873

EP - 875

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9-10

ER -